{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:23:21Z","timestamp":1790504601967,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Romidepsin is a class I selective histone deacetylase (HDAC) inhibitor approved by the Food and Drug Administration (FDA) for relapsed\/refractory (R\/R) cutaneous T\u2010cell lymphoma (CTCL) and peripheral T\u2010cell lymphoma (PTCL), treated with at least one prior systemic therapy. Currently, there is paucity of real\u2010life data on the efficacy and safety of romidepsin in R\/R T\u2010cell lymphoma. This national, multicenter study presents real\u2010life data on the efficacy and safety of romidepsin in R\/R T\u2010cell lymphoma. Patients diagnosed and treated with romidepsin for R\/R CTCL or PTCL between 2013 and 2018 were retrospectively reviewed. Outcomes included overall survival (OS), event\u2010free survival (EFS), overall response rate (ORR), complete response (CR), and adverse events. Fifty\u2010three patients with R\/R PTCL (n = 42) or CTCL (n = 11) were included. Among CTCL patients, median OS was not reached, ORR was 25%, and none achieved CR. Among PTCL patients, median OS was 7.1 months, EFS was 1.9 months, ORR rate was 33%, and 12.5% achieved CR. In a univariate analysis, predictors for longer EFS include any response to therapy, number of previous lines, and PTCL subclass (with better results for angioimmunobalstic T\u2010cell lymphoma). In a univariate and multivariate analysis for OS, treatment response was the only factor predicting OS (OR 4.48; CI 95%, 1.57\u201012.79;\n                    <jats:italic>P<\/jats:italic>\n                    = .005). Most grade 3 and 4 adverse events were hematological (35%). Infections were reported in 34% of patients. This real\u2010life experience with romidepsin confirms the results of the pivotal phase II trials. PTCL subtype and the number of previous lines of therapy have an impact on EFS. In addition, patients who had good response to romidepsin benefited most in terms of both EFS and OS. Efforts should be done to identify those patients.\n                  <\/jats:p>","DOI":"10.1002\/hon.2691","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T21:59:05Z","timestamp":1572559145000},"page":"569-577","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Romidepsin treatment for relapsed or refractory peripheral and cutaneous T\u2010cell lymphoma: Real\u2010life data from a national multicenter observational study"],"prefix":"10.1002","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7245-9652","authenticated-orcid":false,"given":"Shai","family":"Shimony","sequence":"first","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center  Petah Tikva Israel"},{"name":"Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7076-6501","authenticated-orcid":false,"given":"Netanel","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Rambam Hospital  Haifa Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ribakovsky","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"},{"name":"Institute of Hematology Chaim Sheba Medical Center  Ramat Gan Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Rozovski","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center  Petah Tikva Israel"},{"name":"Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Avigdor","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"},{"name":"Institute of Hematology Chaim Sheba Medical Center  Ramat Gan Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Zloto","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Berger","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center  Petah Tikva Israel"},{"name":"Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"},{"name":"Department of Hematology Tel Aviv Sourasky Medical Center  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chava","family":"Perry","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"},{"name":"Department of Hematology Tel Aviv Sourasky Medical Center  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Abadi","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"},{"name":"Hematology Unit, Meir Medical Center  Kfar Saba Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Raanani","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center  Petah Tikva Israel"},{"name":"Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Gafter\u2010Gvili","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center  Petah Tikva Israel"},{"name":"Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"},{"name":"Department of Medicine A, Rabin Medical Center  Petah Tikva Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Gurion","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center  Petah Tikva Israel"},{"name":"Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24876"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1306"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/623924"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.6150"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.9066"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312603"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_6_14_1","unstructured":"US department of health and human services.Common terminology criteria for adverse events v5.0 (CTCAE).Princ Pract Clin Trial Med.2017."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01953.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1137292"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.0004"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2320"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.939"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2095"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-542142"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25463"},{"issue":"1","key":"e_1_2_6_25_1","first-page":"1515","article-title":"A phase 1\/2 study of oral 5\u2010azacitidine and romidepsin in patients with lymphoid malignancies reveals promising activity in heavily pretreated peripheral T\u2010cell lymphoma (PTCL)","volume":"130","author":"Falchi L","year":"2017","journal-title":"Blood"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806737"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.8521"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.220012"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1276287"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2691","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2691","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2691","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T23:17:24Z","timestamp":1694128644000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1002\/hon.2691"],"URL":"https:\/\/doi.org\/10.1002\/hon.2691","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.2691\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2691\/v1\/review1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"2019-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}